Introduction/Background The prognosis of patients with platinum-resistant Epithelial Ovarian Cancer (EOC) remains poor, with few therapeutic choices available, mainly based on non-platinum compounds. This study aims at exploring whether platinum rechallenge may be an option for those patients who experience a platinum-resistant relapse after first line chemotherapy.

Methodology In this retrospective, single-institute, observational study we enrolled all BRCA1/2 wild type (wt) patients who underwent primary cytoreductive surgery for EOC, between January 2017 and July 2021 and relapsed within 6 months after completing first line platinum-based chemotherapy, regardless of maintenance treatment. Patients receiving platinum monotherapy (P) where compared with those receiving pegylated liposomal doxorubicin (PLD), the most used schedule, or non-platinum/non-PLD therapy (paclitaxel or gemcitabine or topotecan, PGT).

• Download figure
• Open in new tab
• Download powerpoint

Abstract #620 Figure 1

PFS, Figure 2 OS

Results Overall, 87 patients were identified, of which 18 (21%) received P, 50 (57%) underwent PLD and 19 (22%) had PGT. Platinum-based arm had a median progression-free survival of 9 months, compared with 4 and 6 months, in PLD and PGT respectively (log rank p = 0.002; P vs PLD

p < 0.001; P vs PGT p = 0.047) (figure 1).

With regard of Overall Survival (OS), patients receiving P achieved a 30-month median OS, compared with 15 and 17 months of PLD and PGT, respectively (log rank p = 0.20; P vs PLD p = 0.067; P vs PGT p = 0.26) (figure 2).

Conclusion Platinum monotherapy is still an option in BRCAWt patients recurring within 6 months from first line treatment, with interesting survival results, compared to standard non-platinum monotherapy, commonly preferred and new targeted drugs.

Disclosures none